Francine Touzard Romo1, Mariam Aziz2, Britt Livak3, Emily Huesgen4, Ben Colton5, Timothy P Flanigan6, Blake Max7, Harold Kessler2. 1. The Miriam Hospital, Providence, RI, USA. 2. Rush University Medical Center, Chicago, IL, USA ; Cook County Health and Hospitals System, Chicago, IL, USA. 3. Cook County Health and Hospitals System, Chicago, IL, USA. 4. University of Illinois at Chicago, Chicago, IL, USA. 5. Resurrection Health Care, Chicago, IL, USA. 6. The Miriam Hospital, Providence, RI, USA ; Warren Alpert Medical School of Brown University, Providence, RI, USA. 7. Ruth M. Rothstein CORE Center, Chicago, IL, USA.
Abstract
BACKGROUND: Tenofovir associated nephrotoxicity (TDFN) is well recognized. This study describes the trend of renal function recovery and virologic consequences after cessation of tenofovir (TDF) for suspected TDFN. METHODS: This was a retrospective chart review of 241 patients who underwent HLA-B*5701 allele testing between January 2007-December 2010. Demographics and clinical characteristics were compared at baseline, 3, 6, and 12 month between patients that continued and discontinued TDF. Factors associated with renal function recovery were assessed by multivariable logistic regression. RESULTS: Eighty patients were identified with TDFN; 84% male, 74% African American (AA) with a median age of 55 years, and median length of TDF use for 122 weeks. Renal recovery at 12 months differed in those who stopped versus (vs.) continued TDF (83% vs. 57% p=0.03). In a crude analysis, baseline chronic kidney disease was negatively associated with renal recovery (p=0.01). An adjusted analysis showed that those who stopped TDF had 3.76 higher odds of renal recovery compared to those who did not stop TDF (95% CI: 1.26-11.27, p=0.02). There were no significant differences in virologic response after switching TDF to an alternative agent. CONCLUSION: In this mostly AA male population with suspected TDFN, discontinuation of TDF was strongly associated with renal function recovery without affecting viral suppression.
BACKGROUND:Tenofovir associated nephrotoxicity (TDFN) is well recognized. This study describes the trend of renal function recovery and virologic consequences after cessation of tenofovir (TDF) for suspected TDFN. METHODS: This was a retrospective chart review of 241 patients who underwent HLA-B*5701 allele testing between January 2007-December 2010. Demographics and clinical characteristics were compared at baseline, 3, 6, and 12 month between patients that continued and discontinued TDF. Factors associated with renal function recovery were assessed by multivariable logistic regression. RESULTS: Eighty patients were identified with TDFN; 84% male, 74% African American (AA) with a median age of 55 years, and median length of TDF use for 122 weeks. Renal recovery at 12 months differed in those who stopped versus (vs.) continued TDF (83% vs. 57% p=0.03). In a crude analysis, baseline chronic kidney disease was negatively associated with renal recovery (p=0.01). An adjusted analysis showed that those who stopped TDF had 3.76 higher odds of renal recovery compared to those who did not stop TDF (95% CI: 1.26-11.27, p=0.02). There were no significant differences in virologic response after switching TDF to an alternative agent. CONCLUSION: In this mostly AA male population with suspected TDFN, discontinuation of TDF was strongly associated with renal function recovery without affecting viral suppression.
Authors: Samir K Gupta; Joseph A Eustace; Jonathan A Winston; Ivy I Boydstun; Tejinder S Ahuja; Rudolph A Rodriguez; Karen T Tashima; Michelle Roland; Nora Franceschini; Frank J Palella; Jeffrey L Lennox; Paul E Klotman; Sharon A Nachman; Stephen D Hall; Lynda A Szczech Journal: Clin Infect Dis Date: 2005-04-22 Impact factor: 9.079
Authors: Leal C Herlitz; Sumit Mohan; Michael B Stokes; Jai Radhakrishnan; Vivette D D'Agati; Glen S Markowitz Journal: Kidney Int Date: 2010-09-01 Impact factor: 10.612
Authors: Anthony E Zimmermann; Thomas Pizzoferrato; John Bedford; Anne Morris; Robert Hoffman; Gregory Braden Journal: Clin Infect Dis Date: 2005-12-08 Impact factor: 9.079
Authors: Paul E Sax; Camlin Tierney; Ann C Collier; Margaret A Fischl; Katie Mollan; Lynne Peeples; Catherine Godfrey; Nasreen C Jahed; Laurie Myers; David Katzenstein; Awny Farajallah; James F Rooney; Belinda Ha; William C Woodward; Susan L Koletar; Victoria A Johnson; P Jan Geiseler; Eric S Daar Journal: N Engl J Med Date: 2009-12-01 Impact factor: 91.245
Authors: Mark R Nelson; Christine Katlama; Julio S Montaner; David A Cooper; Brian Gazzard; Bonaventura Clotet; Adriano Lazzarin; Knud Schewe; Joep Lange; Christina Wyatt; Sue Curtis; Shan-Shan Chen; Stephen Smith; Norbert Bischofberger; James F Rooney Journal: AIDS Date: 2007-06-19 Impact factor: 4.177
Authors: Ravindra L Mehta; John A Kellum; Sudhir V Shah; Bruce A Molitoris; Claudio Ronco; David G Warnock; Adeera Levin Journal: Crit Care Date: 2007 Impact factor: 9.097
Authors: Helen Ndagije; Victoria Nambasa; Elizabeth Namagala; Huldah Nassali; Dan Kajungu; Gordon Sematiko; Sten Olsson; Shanthi Pal Journal: Drug Saf Date: 2015-04 Impact factor: 5.606